Cellivate Technologies, a biotech business, has successfully secured $1 million in a seed funding round. The funding was primarily driven by Antler, with additional participation from Venture Catalysts, Hatcher+, and We Founder Circle.
the cash will be utilized to expedite research and development activities, increase the manufacture of their breakthrough goods, and broaden their market presence.
Cellivate is creating groundbreaking technologies to tackle crucial obstacles in cell culture and biomanufacturing. The company’s primary products include of sophisticated microcarriers used to increase cell growth on a larger scale, as well as an innovative serum derived from cells that is intended to replace fetal bovine serum.
Read also – SigTuple Tuple Secures $4 Mn Funding Round from Sidbi Venture Capital
The market for cell culture, specifically in relation to microcarriers and serum, is projected to achieve a value of $33 billion by the year 2030.
Cellivate claims that it’s sophisticated microcarriers and cell-based serum substitutes have the capacity to decrease expenses, enhance productivity, and tackle ethical issues in cell culture procedures.
About Cellivate Technologies
Founded in 2019 by Dr. Viknish Krishnan Kutty, Cellivate Technologies is a spin-off from the National University of Singapore. they develop and commercialize proprietary products and technologies that solve the bottlenecks faced by cell-based companies at different stages of the value chain.
Want to go deeper into the world of startups and entrepreneurship? Check out these categories on VIESTORIES:
Startup Success Stories: Discover inspiring tales of startups overcoming challenges and achieving success.
Funding Startup News: Stay updated with the latest news and trends in startup funding and investment.
Startup Insights: Dive into in-depth analyses of various industries and market trends to make informed business decisions.
